1. Home
  2. BKU vs BEAM Comparison

BKU vs BEAM Comparison

Compare BKU & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BankUnited Inc.

BKU

BankUnited Inc.

HOLD

Current Price

$47.31

Market Cap

3.4B

Sector

Finance

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$33.72

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BKU
BEAM
Founded
2009
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.0B
IPO Year
2010
2019

Fundamental Metrics

Financial Performance
Metric
BKU
BEAM
Price
$47.31
$33.72
Analyst Decision
Hold
Buy
Analyst Count
12
12
Target Price
$51.58
$50.75
AVG Volume (30 Days)
530.9K
1.8M
Earning Date
04-22-2026
05-06-2026
Dividend Yield
2.87%
N/A
EPS Growth
14.61
82.31
EPS
0.83
N/A
Revenue
$21,732,000.00
$24,000.00
Revenue This Year
$16.26
N/A
Revenue Next Year
$4.78
$33.77
P/E Ratio
$56.33
N/A
Revenue Growth
7.45
33.33
52 Week Low
$33.59
$15.60
52 Week High
$52.11
$36.44

Technical Indicators

Market Signals
Indicator
BKU
BEAM
Relative Strength Index (RSI) 51.31 60.55
Support Level $46.77 $26.96
Resistance Level $47.41 $36.44
Average True Range (ATR) 1.02 2.15
MACD 0.01 0.26
Stochastic Oscillator 42.98 88.60

Price Performance

Historical Comparison
BKU
BEAM

About BKU BankUnited Inc.

BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses. The company also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products including commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Share on Social Networks: